Global pharma major Lupin Limited (Lupin) announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin’s global research and development efforts across branded, generics and specialty products.

Commenting on the appointment, Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin said, “We are very pleased to welcome Shahin to our leadership team. Shahin’s exceptional track record in delivering brands and generics across developed and emerging markets will be valuable to us as we accelerate our evolution into complex generics and specialty while driving growth across all our major markets.

With nearly 30 years' experience in drug development in leading global pharmaceutical companies, Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals. Prior to that Dr. Fesharaki held various leadership positions in Teva, Allergan/Actavis, Watson Pharmaceuticals and Apotex.

Dr. Fesharaki has extensive development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms.